» Articles » PMID: 27259460

A Systematic Review of Studies Examining the Rate of Lung Function Decline in Patients with Cystic Fibrosis

Overview
Date 2016 Jun 5
PMID 27259460
Citations 48
Authors
Affiliations
Soon will be listed here.
Abstract

A systematic review was performed (i) to describe the reported overall rate of progression of CF lung disease quantified as FEV%predicted decline with age, (ii) to summarise identified influencing risk factors and (iii) to review methods used to analyse CF lung disease progression data. A search of publications providing FEV%predicted values over age was conducted in PUBMED and EMBASE. Baseline and rate of FEV%predicted decline were summarised overall and by identified risk factors. Thirty-nine studies were included and reported variable linear rates of lung function decline in patients with CF. The overall weighted mean FEV%predicted over age was graphically summarised and showed a nonlinear, time-variant decline of lung function. Compared to their peers, Pseudomonas aeruginosa infection and pancreatic insufficiency were most commonly associated with lower baseline and more rapid FEV%predicted declines respectively. Considering nonlinear models and drop-out in lung disease progression, analysis is lacking and more studies are warranted.

Citing Articles

Baseline-dependent improvement in CF studies, plausibility of bias.

Graham E, Heltshe S, Magaret A Contemp Clin Trials Commun. 2024; 42:101378.

PMID: 39678155 PMC: 11639362. DOI: 10.1016/j.conctc.2024.101378.


Impact of sinus surgery in people with cystic fibrosis and chronic rhinosinusitis in the era of highly effective modulator therapy: Protocol for a prospective observational study.

Liu C, Fischer J, Alt J, Bodner T, Chowdhury N, Getz A PLoS One. 2024; 19(9):e0310986.

PMID: 39325787 PMC: 11426423. DOI: 10.1371/journal.pone.0310986.


Impact of day-to-day variation in FEV1 on measures of change: A conceptual description.

Magaret A, Graham E, Caverly L, Cromwell E, Paynter A, Rosenfeld M J Cyst Fibros. 2024; 23(5):943-946.

PMID: 39147620 PMC: 11410506. DOI: 10.1016/j.jcf.2024.07.005.


Robust identification of environmental exposures and community characteristics predictive of rapid lung disease progression.

Peterson C, Rao M, Palipana A, Manning E, Vancil A, Ryan P Sci Total Environ. 2024; 950:175348.

PMID: 39117222 PMC: 11349456. DOI: 10.1016/j.scitotenv.2024.175348.


Ceftolozane/Tazobactam for the Treatment of Adults With Cystic Fibrosis: Results From a French Prospective Cohort Study.

Burgel P, Bourge X, Mackosso C, Parquin F Open Forum Infect Dis. 2024; 11(8):ofae391.

PMID: 39108933 PMC: 11303002. DOI: 10.1093/ofid/ofae391.